<p>Tempus AI Inc. has announced the launch of Paige Predict, a new suite of digital pathology applications designed to analyze H&amp;E whole slide images and help inform testing decisions in cancer care. The AI-powered platform predicts the presence or absence of clinically relevant biomarkers from a single slide, aiding physicians even when tissue samples are limited. Built using Paige’s foundation model and a combined dataset from both Tempus and Paige, Paige Predict leverages data from over 200,000 patients and covers 123 biomarkers across 16 cancer types. This launch follows Tempus’s acquisition of Paige and represents an expansion of the company’s offerings in digital pathology and precision medicine. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121403553) on January 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

LABD

Reuters

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Direxion S&P Biotech Bear 3X

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

iShares US Healthcare Providers

Tempus AI

iShares Biotechnology ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

iShares Genomics Immunology and Healthcare ETF

Tradr 2X Long TEM Daily ETF

Tempus AI Launches Paige Predict to Advance Digital Pathology